menu
    • menu
    [{"orgOrder":0,"company":"China Resources Pharmaceutical Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Irbesartan","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"China Resources Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"China Resources Pharmaceutical Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"China Resources Pharmaceutical Group \/ Not Applicable"},{"orgOrder":0,"company":"HUNAN JIUDIAN PHARMACEUTICAL CO LTD","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Irbesartan","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"HUNAN JIUDIAN PHARMACEUTICAL CO LTD","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"HUNAN JIUDIAN PHARMACEUTICAL CO LTD \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"HUNAN JIUDIAN PHARMACEUTICAL CO LTD \/ Not Applicable"},{"orgOrder":0,"company":"HANDOK","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Irbesartan","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"HANDOK \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"HANDOK \/ Sanofi"}]

    Find Clinical Drug Pipeline Developments & Deals for Irbesartan

    Menu

    Irbesartan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            HANDOK

                            South Korea arrow
                            PharmScience R&D
                            Not Confirmed

                            HANDOK

                            South Korea arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Irbesartan,Amlodipine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Sanofi

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Handok and Sanofi Launch “Aprovasc,” a Combination Antihypertensive Drug, in South Korea

                            Details : Aprovasc (Irbesartan + amlodipine) is an angiotensin II receptor blocker, small molecule drug candidate, which is indicated for the treatment of hypertension and diabetic nephropathy.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 01, 2024

                            Lead Product(s) : Irbesartan,Amlodipine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Sanofi

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            China Resources Pharmaceutical Group

                            China arrow
                            PharmScience R&D
                            Not Confirmed

                            China Resources Pharmaceutical Group

                            China arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Irbesartan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            China Resources Double Crane Irbesartan Dispersible Tablet Passes Evaluation

                            Details : Irbesartan is an angiotensin II receptor blocker, small molecule drug candidate, which is indicated for the treatment of hypertension and diabetic nephropathy.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 04, 2021

                            Lead Product(s) : Irbesartan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            HUNAN JIUDIAN PHARMACEUTICAL CO LTD

                            China arrow
                            PharmScience R&D
                            Not Confirmed

                            HUNAN JIUDIAN PHARMACEUTICAL CO LTD

                            China arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Irbesartan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Congratulations to Jiudian Pharmaceutical Irbesartan Tablets Successfully Approved!

                            Details : Irbesartan is an angiotensin II receptor blocker, small molecule drug candidate, which is indicated for the treatment of hypertension and diabetic nephropathy.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 27, 2020

                            Lead Product(s) : Irbesartan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth